Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Socazolimab plus concurrent radiotherapy in locally advanced cervical cancer
ChiCTR2600120434Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of socazolimab in cervical squamous cell carcinoma (CSCC), cervical adenocarcinoma and Adenosquamous Cervical Cancer (ASC), sponsored by Henan Cancer Hospital. Primary endpoints: Median progression-free survival and Median overall survival. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
socazolimab
03
Conditions
cervical squamous cell carcinoma (CSCC)cervical adenocarcinomaAdenosquamous Cervical Cancer (ASC)
Beyond the preview
Go deeper on ChiCTR2600120434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120434.